BRUKER Business Summary

Bruker Corporation (BRKR) operates as a premier developer and manufacturer of high-performance scientific instruments and diagnostic solutions, generating revenue through a mix of high-value capital equipment sales and recurring aftermarket services, including consumables and maintenance contracts. The company is organized into four primary segments: Bruker Scientific Instruments (BSI) BioSpin, which focuses on magnetic resonance technology; BSI CALID, the largest revenue contributor specializing in mass spectrometry and life science tools; BSI Nano, providing advanced X-ray and atomic force microscopy; and Bruker Energy & Supercon Technologies (BEST), which produces superconducting materials for healthcare and energy infrastructure. Bruker maintains a dominant position in the high-end analytical market, particularly in Nuclear Magnetic Resonance (NMR) and mass spectrometry, where it competes directly with industry giants such as Agilent Technologies, Danaher Corporation, Thermo Fisher Scientific, and Bio-Rad Laboratories. The company was founded in 1960 in Karlsruhe, Germany, by Professor Günther Laukien and Emil Bruker, evolving from a pioneer in impulse spectrometers into a global multi-technology leader. Today, the leadership is anchored by Chairman, President, and CEO Frank H. Laukien, Ph.D., the founder's son and largest shareholder, who holds a pedigree from MIT and a Ph.D. in chemical physics from Harvard. He is supported by Executive Vice President and CFO Gerald N. Herman and a seasoned executive team including Mark R. Munch (EVP, Bruker Nano) and Falko Busse (President, Bruker BioSpin). The board of directors was recently strengthened by the January 2026 appointment of diagnostics veteran Jack Phillips, former CEO of Roche Diagnostics North America, while major institutional backing is provided by prominent investors such as Orbis Allan Gray, BlackRock, and Vanguard.